A Phase 2 Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Lassman AB, Wen PY, van den Bent MJ, Plotkin SR, et al. Clin Cancer Res 2021 Nov 2. pii: 1078-0432.CCR-21-2225.

Read + Share

Amedeo Smart

Independent Medical Education

Lassman AB, Wen PY, van den Bent MJ, Plotkin SR, et al. A Phase 2 Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Clin Cancer Res 2021 Nov 2. pii: 1078-0432.CCR-21-2225.
PMID: 34728525